Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
Klin Mikrobiol Infekc Lek ; 24(1): 14-16, 2018 03.
Article in Czech | MEDLINE | ID: mdl-30016534

ABSTRACT

Presented are two cases of vascular prosthesis infections complicated by peritonitis with a lethal course. The authors describe complicated antibiotic therapy with findings, exhausted options for surgical therapy and subsequent decision that the condition was untreatable and palliative care was initiated.


Subject(s)
Blood Vessel Prosthesis/adverse effects , Prosthesis-Related Infections/pathology , Anti-Bacterial Agents/therapeutic use , Fatal Outcome , Humans
2.
New Microbiol ; 34(3): 291-8, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21811750

ABSTRACT

Pseudomonas aeruginosa is one of the most frequent and dangerous pathogens involved in the etiology of severe nosocomial infections. A retrospective observational study was conducted at all intensive care units of the University Hospital in Olomouc, Czech Republic (155 ICU beds). Complete antibiotic utilization data of the ICUs in the period of 1999 to 2008 were processed according to ATC/DDD system and expressed in defined daily doses per 100 bed-days (DBD). Utilization of meropenem, imipenem, ciprofloxacin, ofloxacin, pefloxacin, gentamicin, amikacin, ceftazidime, cefoperazone, cefoperazone/sulbactam and piperacillin/tazobactam was measured. Pseudomonas aeruginosa strains were isolated from clinical material obtained from patients hospitalized in ICUs. During the ten-year period, utilization of the entire group of antibiotics monitored grew. It increased from 23.52 DBD in 1999 to 27.48 DBD in 2008 with a peak of 33.04 DBD in 2007. P. aeruginosa accounted for as much as 42% of pneumonias and 23% of surgical wound infections. Our results show that P. aeruginosa strains became gradually resistant to all antibiotics used in the treatment of the infections caused by them, with the exception of amikacin and piperacillin/tazobactam.


Subject(s)
Anti-Bacterial Agents/pharmacology , Intensive Care Units , Pseudomonas aeruginosa/drug effects , Amikacin/pharmacology , Cefoperazone/pharmacology , Ceftazidime/pharmacology , Ciprofloxacin/pharmacology , Czech Republic , Drug Resistance, Multiple, Bacterial , Gentamicins/pharmacology , Microbial Sensitivity Tests , Penicillanic Acid/analogs & derivatives , Penicillanic Acid/pharmacology , Piperacillin/pharmacology , Sulbactam/pharmacology , Tazobactam
SELECTION OF CITATIONS
SEARCH DETAIL
...